FR3143356A1 - Combination of vitamins B1, B6 and B9 topically - Google Patents
Combination of vitamins B1, B6 and B9 topically Download PDFInfo
- Publication number
- FR3143356A1 FR3143356A1 FR2213769A FR2213769A FR3143356A1 FR 3143356 A1 FR3143356 A1 FR 3143356A1 FR 2213769 A FR2213769 A FR 2213769A FR 2213769 A FR2213769 A FR 2213769A FR 3143356 A1 FR3143356 A1 FR 3143356A1
- Authority
- FR
- France
- Prior art keywords
- salts
- vitamin
- weight
- composition
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000010374 vitamin B1 Nutrition 0.000 title claims abstract description 43
- 239000011691 vitamin B1 Substances 0.000 title claims abstract description 43
- 235000019158 vitamin B6 Nutrition 0.000 title claims abstract description 43
- 239000011726 vitamin B6 Substances 0.000 title claims abstract description 43
- 235000019159 vitamin B9 Nutrition 0.000 title claims abstract description 43
- 239000011727 vitamin B9 Substances 0.000 title claims abstract description 43
- 230000032683 aging Effects 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims description 68
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 38
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 34
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 34
- 229960003495 thiamine Drugs 0.000 claims description 30
- 229940011671 vitamin b6 Drugs 0.000 claims description 29
- 210000003491 skin Anatomy 0.000 claims description 28
- 229930003451 Vitamin B1 Natural products 0.000 claims description 24
- 229930003761 Vitamin B9 Natural products 0.000 claims description 24
- 239000002537 cosmetic Substances 0.000 claims description 24
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 24
- 239000000049 pigment Substances 0.000 claims description 20
- 230000000699 topical effect Effects 0.000 claims description 19
- 210000002510 keratinocyte Anatomy 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 17
- 239000004904 UV filter Substances 0.000 claims description 13
- 229940088594 vitamin Drugs 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- 230000035882 stress Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 claims description 10
- 238000004040 coloring Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- -1 thiamine monohydrate Chemical class 0.000 claims description 8
- 102000011782 Keratins Human genes 0.000 claims description 7
- 108010076876 Keratins Proteins 0.000 claims description 7
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 235000019157 thiamine Nutrition 0.000 claims description 6
- 239000011721 thiamine Substances 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 230000007102 metabolic function Effects 0.000 claims description 5
- 229960003581 pyridoxal Drugs 0.000 claims description 5
- 235000008164 pyridoxal Nutrition 0.000 claims description 5
- 239000011674 pyridoxal Substances 0.000 claims description 5
- 235000008151 pyridoxamine Nutrition 0.000 claims description 5
- 239000011699 pyridoxamine Substances 0.000 claims description 5
- 235000008160 pyridoxine Nutrition 0.000 claims description 5
- 239000011677 pyridoxine Substances 0.000 claims description 5
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 4
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 4
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 4
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 4
- 230000036560 skin regeneration Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000037303 wrinkles Effects 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 230000009758 senescence Effects 0.000 claims description 3
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 241000021559 Dicerandra Species 0.000 claims 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 17
- 239000002609 medium Substances 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- 239000011707 mineral Substances 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 101001110283 Canis lupus familiaris Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 6
- 101001110313 Homo sapiens Ras-related C3 botulinum toxin substrate 2 Proteins 0.000 description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- 102100022129 Ras-related C3 botulinum toxin substrate 2 Human genes 0.000 description 6
- 239000010445 mica Substances 0.000 description 6
- 229910052618 mica group Inorganic materials 0.000 description 6
- 239000012860 organic pigment Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 5
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 5
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 5
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 101001130509 Homo sapiens Ras GTPase-activating protein 1 Proteins 0.000 description 4
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 4
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000000194 fatty acid Chemical class 0.000 description 4
- 229930195729 fatty acid Chemical class 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- 229910052719 titanium Inorganic materials 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 3
- 229940073609 bismuth oxychloride Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- KKJKXQYVUVWWJP-JLHYYAGUSA-N 4-[(e)-(4,7,7-trimethyl-3-oxo-2-bicyclo[2.2.1]heptanylidene)methyl]benzenesulfonic acid Chemical compound CC1(C)C2CCC1(C)C(=O)\C2=C\C1=CC=C(S(O)(=O)=O)C=C1 KKJKXQYVUVWWJP-JLHYYAGUSA-N 0.000 description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010066302 Keratin-19 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- NRCMAYZCPIVABH-UHFFFAOYSA-N Quinacridone Chemical compound N1C2=CC=CC=C2C(=O)C2=C1C=C1C(=O)C3=CC=CC=C3NC1=C2 NRCMAYZCPIVABH-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000420 cerium oxide Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- HEAHZSUCFKFERC-UHFFFAOYSA-N ecamsule Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2=CC(C=C1)=CC=C1C=C1C(=O)C2(CS(O)(=O)=O)CCC1C2(C)C HEAHZSUCFKFERC-UHFFFAOYSA-N 0.000 description 2
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 2
- 229960000655 ensulizole Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000029774 keratinocyte migration Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- ZKATWMILCYLAPD-UHFFFAOYSA-N niobium pentoxide Chemical compound O=[Nb](=O)O[Nb](=O)=O ZKATWMILCYLAPD-UHFFFAOYSA-N 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- POHGLZRQOVBUBS-UHFFFAOYSA-N (2-nitro-3-nitroso-9H-xanthen-1-yl)-(9H-xanthen-1-yl)diazene Chemical compound O1C2=CC=CC=C2CC2=C1C=CC=C2N=NC1=C2CC3=CC=CC=C3OC2=CC(N=O)=C1[N+](=O)[O-] POHGLZRQOVBUBS-UHFFFAOYSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- FWLHAQYOFMQTHQ-UHFFFAOYSA-N 2-N-[8-[[8-(4-aminoanilino)-10-phenylphenazin-10-ium-2-yl]amino]-10-phenylphenazin-10-ium-2-yl]-8-N,10-diphenylphenazin-10-ium-2,8-diamine hydroxy-oxido-dioxochromium Chemical compound O[Cr]([O-])(=O)=O.O[Cr]([O-])(=O)=O.O[Cr]([O-])(=O)=O.Nc1ccc(Nc2ccc3nc4ccc(Nc5ccc6nc7ccc(Nc8ccc9nc%10ccc(Nc%11ccccc%11)cc%10[n+](-c%10ccccc%10)c9c8)cc7[n+](-c7ccccc7)c6c5)cc4[n+](-c4ccccc4)c3c2)cc1 FWLHAQYOFMQTHQ-UHFFFAOYSA-N 0.000 description 1
- ORWUQAQITKSSRZ-UHFFFAOYSA-N 2-hydroxyethyl 4-[bis[2-(2-hydroxyethoxy)ethyl]amino]benzoate Chemical compound OCCOCCN(CCOCCO)C1=CC=C(C(=O)OCCO)C=C1 ORWUQAQITKSSRZ-UHFFFAOYSA-N 0.000 description 1
- 102100022289 60S ribosomal protein L13a Human genes 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102100038778 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229910000906 Bronze Inorganic materials 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000681240 Homo sapiens 60S ribosomal protein L13a Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Chemical class 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 229910009973 Ti2O3 Inorganic materials 0.000 description 1
- 229910009815 Ti3O5 Inorganic materials 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- HEAHZSUCFKFERC-IWGRKNQJSA-N [(2e)-2-[[4-[(e)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C\C(C=C1)=CC=C1\C=C/1C(=O)C2(CS(O)(=O)=O)CCC\1C2(C)C HEAHZSUCFKFERC-IWGRKNQJSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000000129 anionic group Chemical class 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- UHHXUPJJDHEMGX-UHFFFAOYSA-K azanium;manganese(3+);phosphonato phosphate Chemical compound [NH4+].[Mn+3].[O-]P([O-])(=O)OP([O-])([O-])=O UHHXUPJJDHEMGX-UHFFFAOYSA-K 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- YEAYGXLRPMKZBP-KQGICBIGSA-N bis(2-hydroxyethyl)azanium;(e)-3-(4-methoxyphenyl)prop-2-enoate Chemical compound OCCNCCO.COC1=CC=C(\C=C\C(O)=O)C=C1 YEAYGXLRPMKZBP-KQGICBIGSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001055 blue pigment Substances 0.000 description 1
- 239000010974 bronze Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 description 1
- DRVWBEJJZZTIGJ-UHFFFAOYSA-N cerium(3+);oxygen(2-) Chemical class [O-2].[O-2].[O-2].[Ce+3].[Ce+3] DRVWBEJJZZTIGJ-UHFFFAOYSA-N 0.000 description 1
- 229910000422 cerium(IV) oxide Inorganic materials 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- UOUJSJZBMCDAEU-UHFFFAOYSA-N chromium(3+);oxygen(2-) Chemical class [O-2].[O-2].[O-2].[Cr+3].[Cr+3] UOUJSJZBMCDAEU-UHFFFAOYSA-N 0.000 description 1
- QFSKIUZTIHBWFR-UHFFFAOYSA-N chromium;hydrate Chemical compound O.[Cr] QFSKIUZTIHBWFR-UHFFFAOYSA-N 0.000 description 1
- 230000003280 chronobiological effect Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
- XCJYREBRNVKWGJ-UHFFFAOYSA-N copper(II) phthalocyanine Chemical compound [Cu+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 XCJYREBRNVKWGJ-UHFFFAOYSA-N 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- PPSZHCXTGRHULJ-UHFFFAOYSA-N dioxazine Chemical compound O1ON=CC=C1 PPSZHCXTGRHULJ-UHFFFAOYSA-N 0.000 description 1
- GLCJMPWWQKKJQZ-UHFFFAOYSA-L disodium;2-[4-(4,6-disulfonato-1h-benzimidazol-2-yl)phenyl]-1h-benzimidazole-4,6-disulfonate;hydron Chemical compound [Na+].[Na+].C1=C(S(O)(=O)=O)C=C2NC(C3=CC=C(C=C3)C3=NC4=C(C=C(C=C4N3)S(=O)(=O)O)S([O-])(=O)=O)=NC2=C1S([O-])(=O)=O GLCJMPWWQKKJQZ-UHFFFAOYSA-L 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001056 green pigment Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000007886 magnetic bead extraction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Chemical class 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000001053 orange pigment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940032067 peg-20 stearate Drugs 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- DGBWPZSGHAXYGK-UHFFFAOYSA-N perinone Chemical compound C12=NC3=CC=CC=C3N2C(=O)C2=CC=C3C4=C2C1=CC=C4C(=O)N1C2=CC=CC=C2N=C13 DGBWPZSGHAXYGK-UHFFFAOYSA-N 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000767 polyaniline Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- FYNROBRQIVCIQF-UHFFFAOYSA-N pyrrolo[3,2-b]pyrrole-5,6-dione Chemical compound C1=CN=C2C(=O)C(=O)N=C21 FYNROBRQIVCIQF-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102000007268 rho GTP-Binding Proteins Human genes 0.000 description 1
- 108010033674 rho GTP-Binding Proteins Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- KJCLYACXIWMFCC-UHFFFAOYSA-M sodium;5-benzoyl-4-hydroxy-2-methoxybenzenesulfonate Chemical compound [Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 KJCLYACXIWMFCC-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229910052950 sphalerite Inorganic materials 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- PBCFLUZVCVVTBY-UHFFFAOYSA-N tantalum pentoxide Inorganic materials O=[Ta](=O)O[Ta](=O)=O PBCFLUZVCVVTBY-UHFFFAOYSA-N 0.000 description 1
- 239000005460 tetrahydrofolate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- JOUDBUYBGJYFFP-FOCLMDBBSA-N thioindigo Chemical compound S\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2S1 JOUDBUYBGJYFFP-FOCLMDBBSA-N 0.000 description 1
- GQUJEMVIKWQAEH-UHFFFAOYSA-N titanium(III) oxide Chemical compound O=[Ti]O[Ti]=O GQUJEMVIKWQAEH-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- AAAQKTZKLRYKHR-UHFFFAOYSA-N triphenylmethane Chemical compound C1=CC=CC=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 AAAQKTZKLRYKHR-UHFFFAOYSA-N 0.000 description 1
- 235000013799 ultramarine blue Nutrition 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910052984 zinc sulfide Inorganic materials 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Association des vitamines B1, B6 et B9 par voie topique La présente invention concerne l’utilisation des vitamines B1, B6 et B9, notamment par voie topique, pour lutter contre les signes du vieillissement et/ou améliorer la qualité de la peau. Figure pour l'abrégé : néantCombination of vitamins B1, B6 and B9 topically The present invention relates to the use of vitamins B1, B6 and B9, particularly topically, to combat the signs of aging and/or improve the quality of the skin. Figure for the abstract: none
Description
La présente invention concerne l’utilisation cosmétique des vitamines B1, B6 et B9 pour prévenir et/ou lutter contre les signes du vieillissement et/ou améliorer la qualité de la peau.The present invention relates to the cosmetic use of vitamins B1, B6 and B9 to prevent and/or fight against the signs of aging and/or improve the quality of the skin.
La peau humaine est constituée de deux compartiments à savoir un compartiment superficiel, l'épiderme et un compartiment profond, le derme.Human skin is made up of two compartments, namely a superficial compartment, the epidermis, and a deep compartment, the dermis.
L'épiderme est composé principalement de trois types de cellules qui sont les kératinocytes (majoritaires), les mélanocytes et les cellules de Langerhans, qui jouent un rôle primordial dans la réponse immunitaire et en particulier dans la présentation antigénique.The epidermis is mainly composed of three types of cells which are keratinocytes (majority), melanocytes and Langerhans cells, which play a primordial role in the immune response and in particular in antigen presentation.
Le derme fournit à l'épiderme un support solide. C'est également son élément nourricier. Il est principalement constitué de fibroblastes et d'une matrice extracellulaire. On y trouve aussi des leucocytes, des mastocytes et des macrophages tissulaires. Enfin, le derme est traversé par des vaisseaux sanguins et des fibres nerveuses.The dermis provides the epidermis with solid support. It is also its nourishing element. It is mainly made up of fibroblasts and an extracellular matrix. There are also leukocytes, mast cells and tissue macrophages. Finally, the dermis is crossed by blood vessels and nerve fibers.
La peau constitue une barrière contre les agressions extérieures, notamment chimiques et/ou mécaniques, et à ce titre, un certain nombre de réactions de défense contre les facteurs environnementaux (climat, UV, tabac, pollutions...) et/ou les xénobiotiques (comme par exemple certains médicaments) se produisent à son niveau : la peau est constamment soumise à des stress, qu’ils soient d’origine intrinsèque (vieillissement chronologique, dérégulations hormonales, stress psychologique…) ou externe (UV, pollutions…).
The skin constitutes a barrier against external attacks, in particular chemical and/or mechanical, and as such, a certain number of defense reactions against environmental factors (climate, UV, tobacco, pollution, etc.) and/or xenobiotics (such as certain medications) occur at its level: the skin is constantly subjected to stress, whether of intrinsic origin (chronological aging, hormonal dysregulation, psychological stress, etc.) or external (UV, pollution, etc.).
Tous ces stress induisent des altérations métaboliques au niveau cellulaire, qui se traduisent par des changements physiologiques importants au niveau tissulaire et plus largement au niveau de l’organe. Ces phénomènes ont des conséquences directes sur la qualité de la peau et accroissent les signes de l'âge, altèrent ses capacités à se défendre, se régénérer et se réparer.All these stresses induce metabolic alterations at the cellular level, which result in significant physiological changes at the tissue level and more broadly at the organ level. These phenomena have direct consequences on the quality of the skin and increase the signs of aging, altering its ability to defend, regenerate and repair itself.
Il existe donc un besoin pour des actifs capables de restaurer les fonctions métaboliques des cellules cutanées et ainsi améliorer la qualité de la peau et réduire les signes de l'âge.There is therefore a need for active ingredients capable of restoring the metabolic functions of skin cells and thus improving the quality of the skin and reducing the signs of aging.
La Demanderesse a maintenant identifié de façon surprenante l'effet synergique de l'association des vitamines B1, B6 et B9, notamment en application topique sur la peau, pour restaurer la fonction métabolique des kératinocytes. Ces fonctions biologiques sont décrites comme favorisant la régénération épidermique et la fonction barrière cutanée. Ainsi, la restauration de la fonction métabolique des kératinocytes permet d'améliorer la qualité et la texture de la peau (donc de diminuer sa rugosité), mais aussi sa souplesse et sa fermeté, ainsi que de diminuer les rides et ridules.The Applicant has now surprisingly identified the synergistic effect of the combination of vitamins B1, B6 and B9, particularly in topical application to the skin, to restore the metabolic function of keratinocytes. These biological functions are described as promoting epidermal regeneration and skin barrier function. Thus, restoring the metabolic function of keratinocytes makes it possible to improve the quality and texture of the skin (therefore reducing its roughness), but also its flexibility and firmness, as well as reducing fine lines and wrinkles.
Plus largement, ces effets ont pour conséquence de prévenir et/ou diminuer les signes de l'âge, de prévenir et/ou diminuer les processus de sénescence et d’améliorer la régénération de la peau.More broadly, these effects have the effect of preventing and/or reducing the signs of aging, preventing and/or reducing senescence processes and improving skin regeneration.
La présente invention a donc pour objet l’utilisation cosmétique de (i) la vitamine B1 ou l’un de ses sels, (ii) la vitamine B6, l’une de ses formes ou l’un de ses sels, et de (iii) la vitamine B9 ou l’un de ses sels, pour prévenir et/ou lutter contre les signes du vieillissement.The subject of the present invention is therefore the cosmetic use of (i) vitamin B1 or one of its salts, (ii) vitamin B6, one of its forms or one of its salts, and ( iii) vitamin B9 or one of its salts, to prevent and/or fight against the signs of aging.
Par « signes du vieillissement », on entend toutes modifications de l'aspect extérieur de la peau dues au vieillissement qu'il soit chronobiologique et/ou photo-induit, comme par exemple les rides et ridules, la peau flétrie, la peau molle, la peau amincie, le manque d'élasticité et/ou de tonus de la peau.By “signs of aging”, we mean all changes in the external appearance of the skin due to aging, whether chronobiological and/or photo-induced, such as for example wrinkles and fine lines, withered skin, flabby skin, thinned skin, lack of elasticity and/or tone of the skin.
Par « prévenir les signes du vieillissement », on entend empêcher ou retarder l’apparition des signes du vieillissement.By “preventing the signs of aging”, we mean preventing or delaying the appearance of the signs of aging.
La présente invention a également pour objet l’utilisation cosmétique de (i) la vitamine B1 ou l’un de ses sels, (ii) la vitamine B6, l’une de ses formes ou l’un de ses sels, et de (iii) la vitamine B9 ou l’un de ses sels, pour restaurer la fonction métabolique des kératinocytes et/ou stimuler leur régénération cellulaire.The present invention also relates to the cosmetic use of (i) vitamin B1 or one of its salts, (ii) vitamin B6, one of its forms or one of its salts, and ( iii) vitamin B9 or one of its salts, to restore the metabolic function of keratinocytes and/or stimulate their cellular regeneration.
En particulier, la présente invention a pour objet l’utilisation cosmétique de (i) la vitamine B1 ou l’un de ses sels, (ii) la vitamine B6, l’une de ses formes ou l’un de ses sels, et de (iii) la vitamine B9 ou l’un de ses sels, pour améliorer la qualité, la texture et/ou l'apparence de la peau, et/ou pour lutter contre le stress induit par l’environnement, de préférence induit par les UV et/ou la pollution. Elle a également pour objet l’utilisation cosmétique de (i) la vitamine B1 ou l’un de ses sels, (ii) la vitamine B6, l’une de ses formes ou l’un de ses sels, et de (iii) la vitamine B9 ou l’un de ses sels, pour diminuer la rugosité de la peau, et/ou prévenir et/ou diminuer les ridules et les rides. Elle a également pour objet l’utilisation cosmétique de (i) la vitamine B1 ou l’un de ses sels, (ii) la vitamine B6, l’une de ses formes ou l’un de ses sels, et de (iii) la vitamine B9 ou l’un de ses sels, pour améliorer la souplesse, le rebond et/ou la fermeté de la peau.In particular, the present invention relates to the cosmetic use of (i) vitamin B1 or one of its salts, (ii) vitamin B6, one of its forms or one of its salts, and (iii) vitamin B9 or one of its salts, to improve the quality, texture and/or appearance of the skin, and/or to combat stress induced by the environment, preferably induced by UV and/or pollution. It also relates to the cosmetic use of (i) vitamin B1 or one of its salts, (ii) vitamin B6, one of its forms or one of its salts, and (iii) vitamin B9 or one of its salts, to reduce the roughness of the skin, and/or prevent and/or reduce fine lines and wrinkles. It also relates to the cosmetic use of (i) vitamin B1 or one of its salts, (ii) vitamin B6, one of its forms or one of its salts, and (iii) vitamin B9 or one of its salts, to improve the suppleness, bounce and/or firmness of the skin.
La présente invention a également pour objet l’utilisation cosmétique de (i) la vitamine B1 ou l’un de ses sels, (ii) la vitamine B6, l’une de ses formes ou l’un de ses sels, et de (iii) la vitamine B9 ou l’un de ses sels, pour prévenir et/ou diminuer les signes de l'âge, et/ou prévenir et/ou diminuer les processus de sénescence, et/ou améliorer la régénération de la peau.The present invention also relates to the cosmetic use of (i) vitamin B1 or one of its salts, (ii) vitamin B6, one of its forms or one of its salts, and ( iii) vitamin B9 or one of its salts, to prevent and/or reduce the signs of aging, and/or prevent and/or reduce senescence processes, and/or improve skin regeneration.
Les utilisations cosmétiques selon l’invention sont typiquement par voie topique, i.e. par application sur la peau. En particulier, les utilisations selon l’invention ne sont pas par voie orale.The cosmetic uses according to the invention are typically topically, i.e. by application to the skin. In particular, the uses according to the invention are not orally.
La présente invention a également pour objet une composition cosmétique topique comprenant, dans un milieu physiologiquement acceptable :The present invention also relates to a topical cosmetic composition comprising, in a physiologically acceptable medium:
(i) de la vitamine B1 ou l’un de ses sels,(i) vitamin B1 or one of its salts,
(ii) de la vitamine B6, l’une de ses formes ou l’un de ses sels, et(ii) vitamin B6, any of its forms or any of its salts, and
(iii) de la vitamine B9 ou l’un de ses sels, et(iii) vitamin B9 or one of its salts, and
au moins un additif choisi parmi les matières colorantes pigmentaires et les filtres UV.at least one additive chosen from pigment coloring materials and UV filters.
La présente invention a également pour objet un procédé de maquillage et/ou de soin des matières kératiniques, comprenant l’application sur les matières kératiniques d’une composition topique selon l’invention.The present invention also relates to a process for making up and/or caring for keratin materials, comprising the application to the keratin materials of a topical composition according to the invention.
Par « matières kératiniques », on entend la peau et/ou les phanères ; de préférence la peau, de préférence la peau du visage et/ou du cou.By “keratin materials” we mean the skin and/or the integuments; preferably the skin, preferably the skin of the face and/or neck.
La vitamine B1, ou thiamine, est une vitamine hydrosoluble de la famille des vitamines B. Les animaux la trouvent dans leur alimentation, tandis qu’elle est synthétisée par les bactéries, les plantes et les champignons. Elle est indispensable à la transformation des glucides en énergie par le cycle de Krebs et est nécessaire au bon fonctionnement du système nerveux et des muscles.Vitamin B1, or thiamine, is a water-soluble vitamin from the B vitamin family. Animals find it in their food, while it is synthesized by bacteria, plants and fungi. It is essential for the transformation of carbohydrates into energy by the Krebs cycle and is necessary for the proper functioning of the nervous system and muscles.
La vitamine B1 peut être utilisée telle quelle, ou bien sous forme de sel, de préférence la thiamine monohydratée.Vitamin B1 can be used as is, or in salt form, preferably thiamine monohydrate.
De préférence, on utilise la thiamine monohydratée.Preferably, thiamine monohydrate is used.
La vitamine B6 est une vitamine hydrosoluble de la famille des vitamines B, représentée par trois formes principales : la pyridoxine, le pyridoxal et la pyridoxamine. Elle est nécessaire au bon fonctionnement du système nerveux et cutané.Vitamin B6 is a water-soluble vitamin from the B vitamin family, represented by three main forms: pyridoxine, pyridoxal and pyridoxamine. It is necessary for the proper functioning of the nervous and skin systems.
La pyridoxine, le pyridoxal et la pyridoxamine sont des formes convertibles entre elles. Elles peuvent être utilisées telles quelles, ou bien sous forme de sels, de préférence la forme chlorhydrate.Pyridoxine, pyridoxal and pyridoxamine are mutually convertible forms. They can be used as is, or in the form of salts, preferably the hydrochloride form.
De préférence, on utilise le chlorhydrate de pyridoxine.Preferably, pyridoxine hydrochloride is used.
La vitamine B9, ou acide folique, est une vitamine hydrosoluble de la famille des vitamines B. C’est le précurseur métabolique de la coenzyme tétrahydrofolate, impliqué notamment dans la synthèse des bases nucléiques, et de certains acides aminés.Vitamin B9, or folic acid, is a water-soluble vitamin from the B vitamin family. It is the metabolic precursor of the coenzyme tetrahydrofolate, involved in particular in the synthesis of nucleic bases and certain amino acids.
La vitamine B9 peut être utilisée telle quelle, ou bien sous forme d’ion folate (sel).Vitamin B9 can be used as is, or in the form of folate ion (salt).
De préférence, on utilise l’acide folique.Preferably, folic acid is used.
De préférence, les vitamines (i) à (iii) ou leurs sels sont formulées dans une composition cosmétique topique comprenant un milieu physiologiquement acceptable.Preferably, the vitamins (i) to (iii) or their salts are formulated in a topical cosmetic composition comprising a physiologically acceptable medium.
Cette composition cosmétique topique est de préférence liquide. Elle peut être choisie parmi les crèmes, les émulsions, les lotions, les dispersions, les solutions, les gels, les baumes et les sérums; ou bien solide, de préférence choisie parmi les masques et les sticks. De préférence, elle n’est pas sous forme solide, qui convient moins bien à une application topique. Elle peut être utilisée comme produit de soin du visage ou du corps et/ou comme produit de maquillage pour la peau.This topical cosmetic composition is preferably liquid. It can be chosen from creams, emulsions, lotions, dispersions, solutions, gels, balms and serums; or solid, preferably chosen from masks and sticks. Preferably, it is not in solid form, which is less suitable for topical application. It can be used as a facial or body care product and/or as a skin makeup product.
De préférence, la composition cosmétique topique comprend :Preferably, the topical cosmetic composition comprises:
de 0.001% à 20% en poids par rapport au poids total de composition, de préférence de 0.1% à 5% en poids, de préférence de 1 à 5% en poids, de (i) vitamine B1 ou l’un de ses sels, et/oufrom 0.001% to 20% by weight relative to the total weight of composition, preferably from 0.1% to 5% by weight, preferably from 1 to 5% by weight, of (i) vitamin B1 or one of its salts , and or
de 0.001% à 10% en poids par rapport au poids total de composition, de préférence de 0.05% à 5% en poids, de préférence de 0.1% à 1% en poids de (ii) vitamine B6, l’une de ses formes ou l’un de ses sels, et/oufrom 0.001% to 10% by weight relative to the total weight of composition, preferably from 0.05% to 5% by weight, preferably from 0.1% to 1% by weight of (ii) vitamin B6, one of its forms or one of its salts, and/or
de 0.001% à 10% en poids par rapport au poids total de composition, de préférence de 0.05% à 5% en poids, de préférence de 0.1% à 5%, de préférence de 0.1% à 2% de (iii) vitamine B9 ou l’un de ses sels.from 0.001% to 10% by weight relative to the total weight of composition, preferably from 0.05% to 5% by weight, preferably from 0.1% to 5%, preferably from 0.1% to 2% of (iii) vitamin B9 or one of its salts.
De préférence, la composition cosmétique topique comprend au moins un ingrédient choisi parmi les tensioactifs, les matières colorantes pigmentaires, les huiles, les polymères épaississants, les filtres UV, les actifs et leurs mélanges.Preferably, the topical cosmetic composition comprises at least one ingredient chosen from surfactants, pigment coloring materials, oils, thickening polymers, UV filters, active ingredients and their mixtures.
Comme tensioactifs utilisables dans l'invention, on peut citer par exemple tensioactifs anioniques et non ionique, et notamment les esters d'acide gras et de polyéthylène glycol tels que le stéarate de PEG-20, et les esters d'acide gras et de glycérine tels que le stéarate de glycéryle.As surfactants which can be used in the invention, mention may be made, for example, of anionic and non-ionic surfactants, and in particular fatty acid and polyethylene glycol esters such as PEG-20 stearate, and fatty acid and glycerin esters. such as glyceryl stearate.
Les matières colorantes pigmentaires sont typiquement choisies parmi les pigments organiques, les pigments minéraux et les nacres.Pigment coloring materials are typically chosen from organic pigments, mineral pigments and nacres.
Par « pigment minéral », on entend tout pigment qui répond à la définition de l’encyclopédie Ullmann dans le chapitre pigment inorganique. On peut citer, parmi les pigments minéraux utiles dans la présente invention, les oxydes de zirconium ou de cérium, ainsi que les oxydes de zinc, de fer (noir, jaune ou rouge) ou de chrome, le violet de manganèse, le bleu outremer, l’hydrate de chrome et le bleu ferrique, le dioxyde de titane, les poudres métalliques comme la poudre d’aluminium et la poudre de cuivre. Les pigments minéraux suivants peuvent aussi être utilisés : Ta2O5, Ti3O5, Ti2O3, TiO, ZrO2 en mélange avec TiO2, ZrO2, Nb2O5, CeO2, ZnS. Dans le cadre de la présente invention, les pigments minéraux sont plus particulièrement l’oxyde de fer et/ou le dioxyde de titane.By “mineral pigment”, we mean any pigment which meets the definition of the Ullmann encyclopedia in the inorganic pigment chapter. Mention may be made, among the mineral pigments useful in the present invention, of zirconium or cerium oxides, as well as zinc, iron (black, yellow or red) or chromium oxides, manganese violet, ultramarine blue. , chromium hydrate and ferric blue, titanium dioxide, metal powders such as aluminum powder and copper powder. The following mineral pigments can also be used: Ta2O5, Ti3O5, Ti2O3, TiO, ZrO2 mixed with TiO2, ZrO2, Nb2O5, CeO2, ZnS. In the context of the present invention, the mineral pigments are more particularly iron oxide and/or titanium dioxide.
Les nacres peuvent être choisies parmi les pigments nacrés, tels que le mica titane recouvert avec un oxyde de fer, le mica titane recouvert avec de l’oxychlorure de bismuth, le mica titane recouvert avec de l’oxyde de chrome, le mica titane recouvert avec un colorant organique, ainsi que les pigments nacrés à base d’oxychlorure de bismuth. Il peut également s’agir de particules de mica à la surface desquelles sont superposées au moins deux couches successives d’oxydes métalliques et/ou de matières colorantes organiques. On peut également citer, à titre d’exemple de nacres, le mica naturel recouvert d’oxyde de titane, d’oxyde de fer, de pigment naturel ou d’oxychlorure de bismuth. Les nacres peuvent plus particulièrement posséder une couleur ou un reflet jaune, rose, rouge, bronze, orangé, brun, or et/ou cuivré.The nacres can be chosen from pearlescent pigments, such as titanium mica coated with iron oxide, titanium mica coated with bismuth oxychloride, titanium mica coated with chromium oxide, titanium mica coated with with an organic dye, as well as pearlescent pigments based on bismuth oxychloride. It may also be mica particles on the surface of which at least two successive layers of metal oxides and/or organic coloring materials are superimposed. We can also cite, as an example of mother-of-pearl, natural mica coated with titanium oxide, iron oxide, natural pigment or bismuth oxychloride. Mother-of-pearl can more particularly have a yellow, pink, red, bronze, orange, brown, gold and/or copper color or reflection.
Par « pigment organique », on entend tout pigment qui répond à la définition de l’encyclopédie Ullmann dans le chapitre pigment organique. Le pigment organique peut notamment être choisi parmi les composés nitroso, nitro, azo, xanthène, quinoléine, anthraquinone, phtalocyanine, de type complexe métallique, isoindolinone, isoindoline, quinacridone, périnone, pérylène, dicétopyrrolopyrrole, thioindigo, dioxazine, triphénylméthane, quinophtalone.By “organic pigment”, we mean any pigment which meets the definition of the Ullmann encyclopedia in the organic pigment chapter. The organic pigment may in particular be chosen from the compounds nitroso, nitro, azo, xanthene, quinoline, anthraquinone, phthalocyanine, of metal complex type, isoindolinone, isoindoline, quinacridone, perinone, perylene, diketopyrrolopyrrole, thioindigo, dioxazine, triphenylmethane, quinophthalone.
Le ou les pigments organiques peuvent être choisis par exemple parmi le carmin, le noir de carbone, le noir d’aniline, la mélanine, le jaune azo, la quinacridone, le bleu de phtalocyanine, le rouge sorgho, les pigments bleus codifiés dans le Color Index sous les références CI 42090, 69800, 69825, 73000, 74100, 74160, les pigments jaunes codifiés dans le Color Index sous les références CI 11680, 11710, 15985, 19140, 20040, 21100, 21108, 47000, 47005, les pigments verts codifiés dans le Color Index sous les références CI 61565, 61570, 74260, les pigments oranges codifiés dans le Color Index sous les références CI 11725, 15510, 45370, 71105, les pigments rouges codifiés dans le Color Index sous les références CI 12085, 12120, 12370, 12420, 12490, 14700, 15525, 15580, 15620, 15630, 15800, 15850, 15865, 15880, 17200, 26100, 45380, 45410, 58000, 73360, 73915, 75470, et les pigments obtenus par polymérisation oxydante de dérivés indoliques, phénoliques tels qu’ils sont décrits dans le brevet FR 2 679 771.The organic pigment(s) may be chosen for example from carmine, carbon black, aniline black, melanin, azo yellow, quinacridone, phthalocyanine blue, sorghum red, the blue pigments codified in the Color Index under the references CI 42090, 69800, 69825, 73000, 74100, 74160, the yellow pigments codified in the Color Index under the references CI 11680, 11710, 15985, 19140, 20040, 21100, 21108, 47000, 7005, pigments green pigments coded in the Color Index under the references CI 61565, 61570, 74260, orange pigments coded in the Color Index under the references CI 11725, 15510, 45370, 71105, red pigments coded in the Color Index under the references CI 12085, 12120, 12370, 12420, 12490, 14700, 15525, 15580, 15620, 15630, 15800, 15850, 15865, 15880, 17200, 26100, 45380, 45410, 00, 73360, 73915, 75470, and the pigments obtained by oxidative polymerization of indolic and phenolic derivatives as described in patent FR 2 679 771.
Comme huiles utilisables dans l'invention, on peut citer les huiles minérales (huile de vaseline), les huiles d'origine végétale (huile d'avocat, huile de soja), les huiles d'origine animale (lanoline), les huiles de synthèse (perhydrosqualène), les huiles siliconées (cyclométhicone) et les huiles fluorées (perfluoropolyéthers). On peut aussi utiliser comme matières grasses des alcools gras (alcool cétylique), des acides gras, des cires (cire de carnauba, ozokérite).As oils which can be used in the invention, mention may be made of mineral oils (Vaseline oil), oils of vegetable origin (avocado oil, soybean oil), oils of animal origin (lanolin), oils of synthesis (perhydrosqualene), silicone oils (cyclomethicone) and fluorinated oils (perfluoropolyethers). Fatty alcohols (cetyl alcohol), fatty acids, waxes (carnauba wax, ozokerite) can also be used as fats.
Comme polymères épaississants, on peut citer les gélifiants hydrophiles, et en particulier les polymères carboxyvinyliques (carbomer), les copolymères acryliques tels que les copolymères d'acrylates/alkylacrylates, les polyacrylamides, les polysaccharides, les gommes naturelles et les argiles ; et les gélifiants lipophiles, en particulier les argiles modifiées comme les bentones, les sels métalliques d'acides gras, la silice hydrophobe et les polyéthylènes.As thickening polymers, mention may be made of hydrophilic gelling agents, and in particular carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays; and lipophilic gelling agents, particularly modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.
Comme actifs, on peut utiliser notamment les agents hydratants, les agents dépigmentants, les agents antiâges, les agents anti-radicaux libres et leurs mélanges. En cas d'incompatibilité, certains au moins des actifs peuvent être incorporés dans des sphérules, notamment des vésicules ioniques ou non-ioniques et/ou des nanoparticules (nanocapsules et/ou nanosphères), de manière à ce que les actifs incompatibles entre eux soient isolés les uns des autres dans la composition.As active ingredients, moisturizing agents, depigmenting agents, anti-aging agents, anti-free radical agents and mixtures thereof can be used in particular. In the event of incompatibility, at least some of the active ingredients can be incorporated into spherules, in particular ionic or non-ionic vesicles and/or nanoparticles (nanocapsules and/or nanospheres), so that the active ingredients that are incompatible with each other are isolated from each other in the composition.
Les filtres UV sont typiquement choisis parmi les filtres UV organiques et les filtres UV minéraux.UV filters are typically chosen from organic UV filters and mineral UV filters.
Les filtres UV organiques sont notamment choisis parmi les dérivés de dibenzoyl méthane comme l’avobenzone, le Terephthalylidène Dicamphre Acide Sulfonic Acid fabriqué sous le nom "MEXORYL SX" par CHIMEX, les dérivés bis-benzoazolyle tels que décrits dans EP 669 323, et US 2,463,264 et plus particulièrement le composé Disodium Phenyl Dibenzimidazole Tetra-sulfonate vendu sous le nom commercial "NEO HELIOPAN AP" par Haarmann et REIMER, les dérivés d’acide p-aminobenzoïque (PABA) tels que PABA, Glyceryl PABA, et PEG-25 PABA vendu sous le nom "UVINUL P25" par BASF, le Phenylbenzimidazole Sulfonic Acid vendu notamment sous le nom commercial "EUSOLEX 232" par MERCK, l’acide férulique, l’acide salicylique, le DEA methoxycinnamate, le Benzylidène Camphre Acide Sulfonique fabriqué sous le nom "MEXORYL SL" par CHIMEX, et le Camphre Benzalkonium Methosulfate fabriqué sous le nom "MEXORYL SO" par CHIMEX, les dérivés de benzophénone comportant au moins un radical sulfonique, tel que notamment Benzophenone-4 vendu sous le nom commercial " UVINUL MS40" par BASF, Benzophenone-5 et Benzophenone-9.The organic UV filters are chosen in particular from dibenzoyl methane derivatives such as avobenzone, Terephthalylidene Dicamphor Sulfonic Acid manufactured under the name "MEXORYL SX" by CHIMEX, bis-benzoazolyl derivatives as described in EP 669 323, and US 2,463,264 and more particularly the compound Disodium Phenyl Dibenzimidazole Tetra-sulfonate sold under the trade name "NEO HELIOPAN AP" by Haarmann and REIMER, p-aminobenzoic acid (PABA) derivatives such as PABA, Glyceryl PABA, and PEG-25 PABA sold under the name "UVINUL P25" by BASF, Phenylbenzimidazole Sulfonic Acid sold in particular under the trade name "EUSOLEX 232" by MERCK, ferulic acid, salicylic acid, DEA methoxycinnamate, Benzylidene Camphor Sulfonic Acid manufactured under the name "MEXORYL SL" by CHIMEX, and Camphor Benzalkonium Methosulfate manufactured under the name "MEXORYL SO" by CHIMEX, benzophenone derivatives comprising at least one sulfonic radical, such as in particular Benzophenone-4 sold under the trade name "UVINUL MS40" by BASF, Benzophenone-5 and Benzophenone-9.
Les filtres UV minéraux sont notamment choisis parmi le dioxyde de titane, l'oxyde de zincMineral UV filters are chosen in particular from titanium dioxide, zinc oxide
et l'oxyde de cérium.and cerium oxide.
La présente invention a également pour objet une composition cosmétique topique comprenant, dans un milieu physiologiquement acceptable :The present invention also relates to a topical cosmetic composition comprising, in a physiologically acceptable medium:
(i) de la vitamine B1 ou l’un de ses sels,(i) vitamin B1 or one of its salts,
(ii) de la vitamine B6, l’une de ses formes ou l’un de ses sels, et(ii) vitamin B6, any of its forms or any of its salts, and
(iii) de la vitamine B9 ou l’un de ses sels, et(iii) vitamin B9 or one of its salts, and
au moins un additif choisi parmi les matières colorantes pigmentaires et les filtres UV.at least one additive chosen from pigment coloring materials and UV filters.
La matière colorante pigmentaire est notamment décrite ci-dessus, et choisie parmi les pigments organiques, les pigments minéraux et les nacres. De préférence, la composition cosmétique topique comprend au moins 1% en poids, de préférence au moins 3% en poids, de préférence au moins 5% en poids par rapport au poids total de composition, d’au moins une matière colorante pigmentaire.The pigment coloring material is in particular described above, and chosen from organic pigments, mineral pigments and mother-of-pearl. Preferably, the topical cosmetic composition comprises at least 1% by weight, preferably at least 3% by weight, preferably at least 5% by weight relative to the total weight of composition, of at least one pigment coloring material.
Le filtre UV est notamment décrit ci-dessus, et choisi parmi les filtres UV organiques et les filtres UV minéraux. De préférence, la composition cosmétique topique comprend au moins 1% en poids, de préférence au moins 3% en poids, de préférence au moins 5% en poids par rapport au poids total de composition, d’au moins un filtre UV.The UV filter is described in particular above, and chosen from organic UV filters and mineral UV filters. Preferably, the topical cosmetic composition comprises at least 1% by weight, preferably at least 3% by weight, preferably at least 5% by weight relative to the total weight of composition, of at least one UV filter.
De préférence, dans cette composition cosmétique topique, (i) la vitamine B1 ou l’un de ses sels est la thiamine monohydratée, et/ou (ii) la vitamine B6, l’une de ses formes ou l’un de ses sels est choisie parmi la pyridoxine, le pyridoxal, la pyridoxamine et leurs sels, de préférence le chlorhydrate de pyridoxine, et/ou (iii) la vitamine B9 ou l’un de ses sels est l’acide folique.Preferably, in this topical cosmetic composition, (i) vitamin B1 or one of its salts is thiamine monohydrate, and/or (ii) vitamin B6, one of its forms or one of its salts. is chosen from pyridoxine, pyridoxal, pyridoxamine and their salts, preferably pyridoxine hydrochloride, and/or (iii) vitamin B9 or one of its salts is folic acid.
De préférence, la composition cosmétique topique comprend :Preferably, the topical cosmetic composition comprises:
de 0.001% à 20% en poids par rapport au poids total de composition, de préférence de 0.1% à 5% en poids, de préférence de 1 à 5% en poids, de (i) vitamine B1 ou l’un de ses sels, et/oufrom 0.001% to 20% by weight relative to the total weight of composition, preferably from 0.1% to 5% by weight, preferably from 1 to 5% by weight, of (i) vitamin B1 or one of its salts , and or
de 0.001% à 10% en poids par rapport au poids total de composition, de préférence de 0.05% à 5% en poids, de préférence de 0.1% à 1% en poids de (ii) vitamine B6, l’une de ses formes ou l’un de ses sels, et/oufrom 0.001% to 10% by weight relative to the total weight of composition, preferably from 0.05% to 5% by weight, preferably from 0.1% to 1% by weight of (ii) vitamin B6, one of its forms or one of its salts, and/or
de 0.001% à 10% en poids par rapport au poids total de composition, de préférence de 0.05% à 5% en poids, de préférence de 0.1% à 5%, de préférence de 0.1% à 2% de (iii) vitamine B9 ou l’un de ses sels.from 0.001% to 10% by weight relative to the total weight of composition, preferably from 0.05% to 5% by weight, preferably from 0.1% to 5%, preferably from 0.1% to 2% of (iii) vitamin B9 or one of its salts.
La présente invention a également pour objet un procédé de maquillage et/ou de soin des matières kératiniques, comprenant l’application sur les matières kératiniques d’une composition topique selon l’invention.The present invention also relates to a process for making up and/or caring for keratin materials, comprising the application to the keratin materials of a topical composition according to the invention.
L’invention est maintenant illustrée par les exemples suivants.The invention is now illustrated by the following examples.
Les légendes des figures sont les suivantes :The figure legends are as follows:
Exemple 1 :Example 1: EE valuation de l’efficacité sur la migration et la prolifération des kératinocytesevaluation of the effectiveness on the migration and proliferation of keratinocytes
Principe: Principle :
Le but de cette étude est d’évaluer les effets des vitamines sur l’expression de transcrits (ARNm) impliqués dans la migration et la prolifération des kératinocytes, processus-clés de la ré-épithélialisation, par RT-qPCR.The aim of this study is to evaluate the effects of vitamins on the expression of transcripts (mRNA) involved in the migration and proliferation of keratinocytes, key processes in re-epithelialization, by RT-qPCR.
Les vitamines B1, B6 et B9, ont été testées seules ou en association, respectivement à 2, 0.3 et 0.1 mg/ml.Vitamins B1, B6 and B9 were tested alone or in combination, respectively at 2, 0.3 and 0.1 mg/ml.
Les différents marqueurs étudiés sont : CEACAM6, RAC2, RASA1, KRT19 et HBEGF.The different markers studied are: CEACAM6, RAC2, RASA1, KRT19 and HBEGF.
Matériels et méthodes: Materials and methods :
Les kératinocytes ont été ensemencés en plaques 48 puits et cultivés pendant 72 heures avec renouvellement du milieu de culture après 24 heures d’incubation. Le milieu a ensuite été renouvelé par du milieu de culture contenant ou non (Témoin), la Vitamine B1 à 2 mg/ml, ou la vitamine B6 à 0.3 mg/ml, ou la Vitamine B9 à 0.1 mg/ml ou l’association des Vitamines B1, B6 et B9 respectivement à 2, 0.3 et 0.1 mg/ml. Les cellules ont ensuite été incubées pendant 24 heures additionnelles. Toutes les conditions ont été réalisées en n=3.The keratinocytes were seeded in 48-well plates and cultured for 72 hours with renewal of the culture medium after 24 hours of incubation. The medium was then renewed with culture medium containing or not (Control), Vitamin B1 at 2 mg/ml, or vitamin B6 at 0.3 mg/ml, or Vitamin B9 at 0.1 mg/ml or the combination Vitamins B1, B6 and B9 respectively at 2, 0.3 and 0.1 mg/ml. The cells were then incubated for an additional 24 hours. All conditions were carried out in n=3.
A la fin des traitements, les milieux de cultures ont été éliminés et les cellules ont été rincées 2 fois en PBS (w/o CaCl2, w/o MgCl2). Les ARN totaux ont ensuite été isolés à l’aide d’un kit d’extraction par billes magnétiques et selon les recommandations du fournisseur (MagMAXTM-96 Total RNA Isolation Kit, Ambion). La quantification des ARN et le contrôle de leur qualité ont été analysés à l’aide du Labchip GX (Perkin Elmer).At the end of the treatments, the culture media were removed and the cells were rinsed twice in PBS (w/o CaCl2, w/o MgCl2). Total RNA was then isolated using a magnetic bead extraction kit and according to the supplier's recommendations (MagMAXTM-96 Total RNA Isolation Kit, Ambion). RNA quantification and quality control were analyzed using Labchip GX (Perkin Elmer).
L’expression des transcrits sélectionnés a été analysée par PCR quantitative en 2 étapes. Tout d’abord, les ADNc ont été retro-transcrits à partir des ARN en utilisant le kit Quantitect® Reverse transcription (QIAGEN) et selon les recommandations du fournisseur. Les expériences de PCR quantitatives ont ensuite été réalisées à l’aide d’un système LightCycler® 480 Real-Time PCR System en plaque 384 puits (Roche) et selon la technique d’incorporation du SYBR®Green (Roche).The expression of the selected transcripts was analyzed by quantitative PCR in 2 steps. First, the cDNAs were reverse transcribed from the RNA using the Quantitect® Reverse transcription kit (QIAGEN) and according to the supplier's recommendations. The quantitative PCR experiments were then carried out using a LightCycler® 480 Real-Time PCR System in a 384-well plate (Roche) and using the SYBR®Green incorporation technique (Roche).
Résultats et conclusions: Results and conclusions :
Les résultats sont exprimés en facteur de modulation (Fc, fold change) par rapport au témoin non traité après normalisation des expressions relatives par rapport à l’expression de gènes de ménage (GAPDH et RPL13A). L’expression d’un gène est considérée comme stimulée lorsqu’elle est multipliée au minimum par 1.5.The results are expressed as modulation factor (Fc, fold change) compared to the untreated control after normalization of relative expressions compared to the expression of housekeeping genes (GAPDH and RPL13A). The expression of a gene is considered to be stimulated when it is multiplied at least by 1.5.
Les résultats montrent que la Vitamine B1 testée à 2 mg/ml stimule faiblement mais significativement l’expression de RAC2, sans moduler l’expression des autres marqueurs, que la Vitamine B6 testée à 0.3 mg/ml stimule l’expression de CEACAM6, RAC2 et KRT19 et enfin, que la Vitamine B9 testée à 0.1 mg/ml stimule l’expression de CEACAM6, RAC2 et KRT19 (Figures 1 & 2). De façon surprenante et inattendue, l’association des 3 vitamines B1, B6 et B9 testées respectivement à 2, 0.3 et 0.1 mg/ml stimule, de façon synergique l’expression de l’ensemble des marqueurs CEACAM6, RAC2, RASA1, KRT19 et HBEGF. Les facteurs de modulations sont très nettement et significativement supérieurs à la somme des effets observées avec les vitamines testées seules et seule la combinaison des 3 vitamines permet de stimuler significativement l’expression des marqueurs RASA1 et HBEGF. Tous ces éléments démontrent ainsi l’activité synergique du mélange. Les marqueurs CEACAM6 (Akihiko F, Kiyofumi E, Yumi H, Masahide K, Masatoshi J and Hironobu I. CEA (Carcinoembryonic Antigen) and CEACAM6 (CEA-Related Cell Adhesion Molecul 6) are Expressed in Psoriasis Vulgaris. The Open Dermatology Journal, 2013, 7, 47-52), RAC2 (Ridley AJ. Rho GTPase signalling in cell migration. Curr Opin Cell Biol. 2015 Oct;36:103-12) et RASA1 (Fitsialos G, Chassot AA, Turchi L, Dayem MA, LeBrigand K, Moreilhon C, Meneguzzi G, Buscà R, Mari B, Barbry P, Ponzio G. Transcriptional signature of epidermal keratinocytes subjected to in vitro scratch wounding reveals selective roles for ERK1/2, p38, and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem. 2007 May 18;282(20):15090-102) codent pour des protéines impliquées dans la migration des kératinocytes alors que les marqueurs KRT19 (Michel M, Török N, Godbout MJ, Lussier M, Gaudreau P, Royal A, Germain L. Keratin 19 as a biochemical marker of skin stem cells in vivo and in vitro: keratin 19 expressing cells are differentially localized in function of anatomic sites, and their number varies with donor age and culture stage. J Cell Sci. 1996 May;109 (Pt 5):1017-28) et HBEGF (Yoshida A, Kanno H, Watabe D, Akasaka T, Sawai T. The role of heparin-binding EGF-like growth factor and amphiregulin in the epidermal proliferation of psoriasis in cooperation with TNFalpha. Arch Dermatol Res. 2008 Jan;300(1):37-45) sont impliqués dans la prolifération des kératinocytes.The results show that Vitamin B1 tested at 2 mg/ml weakly but significantly stimulates the expression of RAC2, without modulating the expression of other markers, that Vitamin B6 tested at 0.3 mg/ml stimulates the expression of CEACAM6, RAC2 and KRT19 and finally, that Vitamin B9 tested at 0.1 mg/ml stimulates the expression of CEACAM6, RAC2 and KRT19 (Figures 1 & 2). Surprisingly and unexpectedly, the combination of the 3 vitamins B1, B6 and B9 tested respectively at 2, 0.3 and 0.1 mg/ml synergistically stimulates the expression of all the markers CEACAM6, RAC2, RASA1, KRT19 and HBEGF. The modulation factors are very clearly and significantly greater than the sum of the effects observed with the vitamins tested alone and only the combination of the 3 vitamins makes it possible to significantly stimulate the expression of the RASA1 and HBEGF markers. All these elements thus demonstrate the synergistic activity of the mixture. CEACAM6 markers (Akihiko F, Kiyofumi E, Yumi H, Masahide K, Masatoshi J and Hironobu I. CEA (Carcinoembryonic Antigen) and CEACAM6 (CEA-Related Cell Adhesion Molecul 6) are Expressed in Psoriasis Vulgaris. The Open Dermatology Journal, 2013 , 7, 47-52), RAC2 (Ridley AJ. Rho GTPase signaling in cell migration. Curr Opin Cell Biol. 2015 Oct;36:103-12) and RASA1 (Fitsialos G, Chassot AA, Turchi L, Dayem MA, LeBrigand K, Moreilhon C, Meneguzzi G, Buscà R, Mari B, Barbry P, Ponzio G. Transcriptional signature of epidermal keratinocytes subjected to in vitro scratch wounding reveals selective roles for ERK1/2, p38, and phosphatidylinositol 3-kinase signaling pathways J. Biol Chem. 2007 May 18;282(20):15090-102) encode proteins involved in keratinocyte migration while the KRT19 markers (Michel M, Török N, Godbout MJ, Lussier M, Gaudreau P, Royal A, Germain L. Keratin 19 as a biochemical marker of skin stem cells in vivo and in vitro: keratin 19 expressing cells are differentially localized in function of anatomic sites, and their number varies with donor age and culture stage. J Cell Sci. 1996 May;109 (Pt 5):1017-28) and HBEGF (Yoshida A, Kanno H, Watabe D, Akasaka T, Sawai T. The role of heparin-binding EGF-like growth factor and amphiregulin in the epidermal proliferation of psoriasis in cooperation with TNFalpha. Arch Dermatol Res. 2008 Jan;300(1):37-45) are involved in the proliferation of keratinocytes.
La combinaison des vitamines B1, B6 et B9 présente donc un intérêt dans le vieillissement cutané en favorisant le renouvellement épidermique, l’épaisseur de l’épiderme diminuant avec l’âge(Branchet MC, Boisnic S, Frances C, Robert AM. Skin thickness changes in normal aging skin. Gerontology. 1990;36(1):28-35. doi: 10.1159/000213172. PMID: 2384222),et dans la régénération cutanée et la cicatrisation, la migration et la prolifération des kératinocytes étant des mécanismes clés dans le processus de ré - épithélialisation(Patricia Rousselle, Fabienne Braye, Guila Dayan. Re-epithelialization of adult skin wounds: cellular mechanisms and therapeutic strategies. Advanced Drug Delivery Reviews, Elsevier, 2019, 146, pp.344- 365. ff10.1016/j.addr.2018.06.019ff. ffhal-03035503f). The combination of vitamins B1, B6 and B9 is therefore of interest in skin aging by promoting epidermal renewal, with the thickness of the epidermis decreasing with age (Branchet MC, Boisnic S, Frances C, Robert AM. Skin thickness changes in normal aging skin. 1990;36(1):28-35. doi: 10.1159/000213172. PMID: 2384222), and in skin regeneration and healing, keratinocyte migration and proliferation being key mechanisms. in the process of re - epithelialization (Patricia Rousselle, Fabienne Braye, Guila Dayan. Re-epithelialization of adult skin wounds: cellular mechanisms and therapeutic strategies. Advanced Drug Delivery Reviews, Elsevier, 2019, 146, pp.344-365. ff10. 1016/j.addr.2018.06.019ff. ffhal-03035503f).
Exemple 2Example 2 : E: E valuation de l’efficacité sur la production de NAD dans des conditions de stress induit par les UV ou par traitement à l’Hevaluation of the effectiveness on NAD production under conditions of stress induced by UV or by treatment with H 22 OO 22
Principe: Principle :
Le but de cette étude est d’évaluer les effets des vitamines sur la protection des kératinocytes vis-à-vis de la déplétion en NAD induite par un stress oxydant à la suite d’une irradiation UV ou suite à un traitement à l’H2O2.The aim of this study is to evaluate the effects of vitamins on the protection of keratinocytes against NAD depletion induced by oxidative stress following UV irradiation or following H treatment. 2 O 2 .
Les vitamines B1, B6 et B9, ont été testées seules ou en association, respectivement à 2, 0.3 et 0.1 mg/ml.Vitamins B1, B6 and B9 were tested alone or in combination, respectively at 2, 0.3 and 0.1 mg/ml.
Le marqueur étudié est une quantification de la concentration en NAD rapportée à la concentration totale en protéines.The marker studied is a quantification of the NAD concentration relative to the total protein concentration.
Matériels et méthodes: Materials and methods :
Les kératinocytes ont été ensemencés dans des plaques 12 puits et cultivés pendant 72 heures dans du milieu de culture.Keratinocytes were seeded in 12-well plates and cultured for 72 hours in culture medium.
- Conditions stimulées par H2O2 :- Conditions stimulated by H2O2:
Le milieu a ensuite été remplacé par du milieu contenant ou non (témoin), la Vitamine B1 à 2 mg/ml, ou la vitamine B6 à 0.3 mg/ml, ou la Vitamine B9 à 0.1 mg/ml ou l’association des Vitamines B1, B6 et B9 respectivement à 2, 0.3 et 0.1 mg/ml et les cellules ont été pré-incubées pendant 24 heures. Après la pré-incubation, le milieu a été collecté et les cellules ont été stimulées pendant 2 heures par 250 µM d’H2O2. Le milieu a ensuite été remplacé par le milieu collecté préalablement et les cellules ont été incubées pendant 48 heures supplémentaires. Toutes les conditions expérimentales ont été réalisées en n=3.The medium was then replaced with medium containing or not (control), Vitamin B1 at 2 mg/ml, or vitamin B6 at 0.3 mg/ml, or Vitamin B9 at 0.1 mg/ml or the combination of Vitamins B1, B6 and B9 at 2, 0.3 and 0.1 mg/ml respectively and the cells were pre-incubated for 24 hours. After the pre-incubation, the medium was collected and the cells were stimulated for 2 hours with 250 µM H 2 O 2 . The medium was then replaced with the previously collected medium and the cells were incubated for an additional 48 hours. All experimental conditions were carried out in n=3.
- Conditions d'irradiation aux UV :- UV irradiation conditions:
Le milieu a ensuite été remplacé par du milieu contenant ou non (témoin), la Vitamine B1 à 667 µg/ml, ou la vitamine B6 à 100 µg/ml, ou la Vitamine B9 à 33.3 µg/ml ou l’association des Vitamines B1, B6 et B9 respectivement à 667, 100 et 33.3 µg/ml et les cellules ont été pré-incubées pendant 24 heures. Après la pré-incubation, le milieu a été collecté et remplacé par du milieu d’irradiation et les cellules ont été irradiées avec des UVB à 275 mJ/cm2 (+ UVA à 2,1 J/cm2). La lampe utilisée était un simulateur solaire SOL500 équipé d'un filtre H2 (Dr. Hönle, AG). Le milieu a ensuite été remplacé par le milieu collecté préalablement et les cellules ont été incubées pendant 48 heures supplémentaires. Toutes les conditions expérimentales ont été réalisées en n=3.The medium was then replaced with medium containing or not (control), Vitamin B1 at 667 µg/ml, or vitamin B6 at 100 µg/ml, or Vitamin B9 at 33.3 µg/ml or the combination of Vitamins B1, B6 and B9 at 667, 100 and 33.3 µg/ml respectively and the cells were pre-incubated for 24 hours. After pre-incubation, the medium was collected and replaced with irradiation medium and the cells were irradiated with UVB at 275 mJ/cm2 (+UVA at 2.1 J/cm2). The lamp used was a SOL500 solar simulator equipped with an H2 filter (Dr. Hönle, AG). The medium was then replaced with the previously collected medium and the cells were incubated for an additional 48 hours. All experimental conditions were carried out in n=3.
A la fin des traitements, les milieux ont été éliminés et la quantité de NAD a été quantifiée à l’aide d’un kit de dosage spécifique et selon les recommandations du fournisseurs (BioVision, #K337-100). La quantité de protéines dans chaque puits de culture a aussi été quantifiée à l’aide d’un kit spécifique et toujours selon les recommandations du fournisseur (BIO-RAD, #500-0116).At the end of the treatments, the media were removed and the quantity of NAD was quantified using a specific assay kit and according to the supplier's recommendations (BioVision, #K337-100). The quantity of proteins in each culture well was also quantified using a specific kit and always according to the supplier's recommendations (BIO-RAD, #500-0116).
Un pourcentage de protection vis-à-vis des stress a été calculé selon la formule :A percentage of protection against stress was calculated according to the formula:
[NAD] Traitement : concentration en NAD (pmol/mg de protéines) dans les conditions traitées,[ NAD ] Treatment : NAD concentration (pmol/mg of protein) under the treated conditions,
[NAD] Témoin stimulé : concentration en NAD (pmol/mg de protéines) dans les témoins stimulés par H2O2ou UVs,[ NAD ] Stimulated control : NAD concentration (pmol/mg of proteins) in controls stimulated by H 2 O 2 or UVs,
[NAD] Contrôle no n stimulé : concentration en NAD (pmol/mg de protéines) dans les conditions non stimulées.[ NAD ] Unstimulated control : NAD concentration (pmol/mg protein) under unstimulated conditions.
Résultats et conclusions: Results and conclusions :
Les résultats montrent que les deux stress, UV et H2O2, ont induit une diminution nette de la concentration intracellulaire en NAD (Figures 3 et 4). Dans ces conditions, seule la Vitamine B6, testée seule à 0.3 mg/ml, a significativement permis de protéger les kératinocytes du stress induit par le traitement à l’H2O2(
Sachant qu’augmenter le NAD permet de ralentir le vieillissement (Conlon NJ. The Role of NAD+ in Regenerative Medicine. Plast Reconstr Surg. 2022 Oct 1;150(4 Suppl):41S-48S),ces résultats démontrent l’intérêt de la combinaison des vitamines B1, B6 et B9 pour lutter contre les signes du vieillissement. Knowing that increasing NAD helps slow aging (Conlon NJ. The Role of NAD+ in Regenerative Medicine. Plast Reconstr Surg. 2022 Oct 1;150(4 Suppl):41S-48S), these results demonstrate the interest of combination of vitamins B1, B6 and B9 to fight the signs of aging.
Claims (17)
de 0.001% à 20% en poids par rapport au poids total de composition, de préférence de 0.1% à 5% en poids, de préférence de 1 à 5% en poids, de (i) vitamine B1 ou l’un de ses sels, et/ou
de 0.001% à 10% en poids par rapport au poids total de composition, de préférence de 0.05% à 5% en poids, de préférence de 0.1% à 1% en poids de (ii) vitamine B6, l’une de ses formes ou l’un de ses sels, et/ou
de 0.001% à 10% en poids par rapport au poids total de composition, de préférence de 0.05% à 5% en poids, de préférence de 0.1% à 5%, de préférence de 0.1% à 2% de (iii) vitamine B9 ou l’un de ses sels.Use according to claim 11 or 12, characterized in that the topical cosmetic composition comprises:
from 0.001% to 20% by weight relative to the total weight of composition, preferably from 0.1% to 5% by weight, preferably from 1 to 5% by weight, of (i) vitamin B1 or one of its salts , and or
from 0.001% to 10% by weight relative to the total weight of composition, preferably from 0.05% to 5% by weight, preferably from 0.1% to 1% by weight of (ii) vitamin B6, one of its forms or one of its salts, and/or
from 0.001% to 10% by weight relative to the total weight of composition, preferably from 0.05% to 5% by weight, preferably from 0.1% to 5%, preferably from 0.1% to 2% of (iii) vitamin B9 or one of its salts.
(i) de la vitamine B1 ou l’un de ses sels,
(ii) de la vitamine B6, l’une de ses formes ou l’un de ses sels, et
(iii) de la vitamine B9 ou l’un de ses sels, et
au moins un additif choisi parmi les matières colorantes pigmentaires et les filtres UV.Topical cosmetic composition comprising, in a physiologically acceptable medium:
(i) vitamin B1 or one of its salts,
(ii) vitamin B6, one of its forms or one of its salts, and
(iii) vitamin B9 or one of its salts, and
at least one additive chosen from pigment coloring materials and UV filters.
de 0.001% à 20% en poids par rapport au poids total de composition, de préférence de 0.1% à 5% en poids, de préférence de 1 à 5% en poids, de (i) vitamine B1 ou l’un de ses sels, et/ou
de 0.001% à 10% en poids par rapport au poids total de composition, de préférence de 0.05% à 5% en poids, de préférence de 0.1% à 1% en poids de (ii) vitamine B6, l’une de ses formes ou l’un de ses sels, et/ou
de 0.001% à 10% en poids par rapport au poids total de composition, de préférence de 0.05% à 5% en poids, de préférence de 0.1% à 5%, de préférence de 0.1% à 2% de (iii) vitamine B9 ou l’un de ses sels.Composition according to claim 14 or 15, characterized in that it comprises:
from 0.001% to 20% by weight relative to the total weight of composition, preferably from 0.1% to 5% by weight, preferably from 1 to 5% by weight, of (i) vitamin B1 or one of its salts , and or
from 0.001% to 10% by weight relative to the total weight of composition, preferably from 0.05% to 5% by weight, preferably from 0.1% to 1% by weight of (ii) vitamin B6, one of its forms or one of its salts, and/or
from 0.001% to 10% by weight relative to the total weight of composition, preferably from 0.05% to 5% by weight, preferably from 0.1% to 5%, preferably from 0.1% to 2% of (iii) vitamin B9 or one of its salts.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2213769A FR3143356A1 (en) | 2022-12-19 | 2022-12-19 | Combination of vitamins B1, B6 and B9 topically |
| PCT/EP2023/086338 WO2024133074A1 (en) | 2022-12-19 | 2023-12-18 | Association of vitamins b1, b6 and b9 via the topical route |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2213769 | 2022-12-19 | ||
| FR2213769A FR3143356A1 (en) | 2022-12-19 | 2022-12-19 | Combination of vitamins B1, B6 and B9 topically |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR3143356A1 true FR3143356A1 (en) | 2024-06-21 |
Family
ID=85461979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR2213769A Pending FR3143356A1 (en) | 2022-12-19 | 2022-12-19 | Combination of vitamins B1, B6 and B9 topically |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR3143356A1 (en) |
| WO (1) | WO2024133074A1 (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2463264A (en) | 1942-12-23 | 1949-03-01 | Ciba Ltd | Derivatives of cyclic amidines and process of making same |
| FR2679771A1 (en) | 1991-08-01 | 1993-02-05 | Oreal | Use of an insoluble pigment obtained by oxidative polymerisation of indole derivatives for the temporary dyeing of keratinous fibres |
| EP0669323A1 (en) | 1994-02-24 | 1995-08-30 | Haarmann & Reimer Gmbh | Utilization of benzazols as UV-absorbers, new benzazoles and process for their preparation |
| US20030190337A1 (en) * | 2002-03-28 | 2003-10-09 | The Procter & Gamble Company | Methods for regulating the condition of mammalian keratinous tissue via topical application of vitamin B6 compositions |
| KR20040014684A (en) * | 2002-08-10 | 2004-02-18 | 김옥태 | Making the combination of Octacosanol, Collagen, VitaminC, Citric acid and VitaminB1, being the largest of effect in the beauty art of skin and body |
| WO2007014643A1 (en) * | 2005-08-01 | 2007-02-08 | Beiersdorf Ag | Stable active-substance combinations based on folic acid |
| WO2015062615A1 (en) * | 2013-10-29 | 2015-05-07 | Robert Peter Taylor | Composition for the effects of winter aging on the skin |
| CN108703927A (en) * | 2018-07-25 | 2018-10-26 | 宁波博睿修存生物科技有限公司 | Anti-age corrective eye treatment cream |
| WO2021165623A1 (en) * | 2020-02-19 | 2021-08-26 | Bianchin Claire | Novel cosmetic and/or dermatologic composition with osmotic synergy and related production method |
-
2022
- 2022-12-19 FR FR2213769A patent/FR3143356A1/en active Pending
-
2023
- 2023-12-18 WO PCT/EP2023/086338 patent/WO2024133074A1/en unknown
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2463264A (en) | 1942-12-23 | 1949-03-01 | Ciba Ltd | Derivatives of cyclic amidines and process of making same |
| FR2679771A1 (en) | 1991-08-01 | 1993-02-05 | Oreal | Use of an insoluble pigment obtained by oxidative polymerisation of indole derivatives for the temporary dyeing of keratinous fibres |
| EP0669323A1 (en) | 1994-02-24 | 1995-08-30 | Haarmann & Reimer Gmbh | Utilization of benzazols as UV-absorbers, new benzazoles and process for their preparation |
| US20030190337A1 (en) * | 2002-03-28 | 2003-10-09 | The Procter & Gamble Company | Methods for regulating the condition of mammalian keratinous tissue via topical application of vitamin B6 compositions |
| KR20040014684A (en) * | 2002-08-10 | 2004-02-18 | 김옥태 | Making the combination of Octacosanol, Collagen, VitaminC, Citric acid and VitaminB1, being the largest of effect in the beauty art of skin and body |
| WO2007014643A1 (en) * | 2005-08-01 | 2007-02-08 | Beiersdorf Ag | Stable active-substance combinations based on folic acid |
| WO2015062615A1 (en) * | 2013-10-29 | 2015-05-07 | Robert Peter Taylor | Composition for the effects of winter aging on the skin |
| CN108703927A (en) * | 2018-07-25 | 2018-10-26 | 宁波博睿修存生物科技有限公司 | Anti-age corrective eye treatment cream |
| WO2021165623A1 (en) * | 2020-02-19 | 2021-08-26 | Bianchin Claire | Novel cosmetic and/or dermatologic composition with osmotic synergy and related production method |
Non-Patent Citations (16)
| Title |
|---|
| AKIHIKO FKIYOFUMI EYUMI HMASAHIDE KMASATOSHI JHIRONOBU I.: "CEA (Carcinoembryonic Antigen) and CEACAM6 (CEA-Related Cell Adhesion Molecul 6) arc Expressed in Psoriasis Vulgaris", THE OPEN DERMATOLOGY JOURNAL, vol. 7, 2013, pages 47 - 52 |
| BRANCHET MCBOISNIC SFRANCES CROBERT AM: "Skin thickness changes in normal aging skin", GERONTOLOGY, vol. 36, no. 1, 1990, pages 28 - 35 |
| CONLON NJ: "The Rôle of NAD+ in Regenerative Medicine", PLAST RECONSTR SURG, vol. 150, 1 October 2022 (2022-10-01), pages 41S - 48S |
| DATABASE GNPD [online] MINTEL; 1 March 2019 (2019-03-01), ANONYMOUS: "[Powder] Pro-Perfection Translucent Powder", XP093058677, retrieved from https://www.gnpd.com/sinatra/recordpage/6381777/ Database accession no. 6381777 * |
| DATABASE GNPD [online] MINTEL; 10 August 2022 (2022-08-10), ANONYMOUS: "Glow Cushion", XP093058688, retrieved from https://www.gnpd.com/sinatra/recordpage/9794926/ Database accession no. 9794926 * |
| DATABASE GNPD [online] MINTEL; 12 April 2021 (2021-04-12), ANONYMOUS: "+CT50 Eye Energize Regenerating Cream", XP093058803, retrieved from https://www.gnpd.com/sinatra/recordpage/8581497/ Database accession no. 8581497 * |
| DATABASE GNPD [online] MINTEL; 12 December 2018 (2018-12-12), ANONYMOUS: "[Fluid] Pro-Perfection Tinted Fluid SPF 30", XP093058663, retrieved from https://www.gnpd.com/sinatra/recordpage/6206085/ Database accession no. 6206085 * |
| DATABASE GNPD [online] MINTEL; 14 October 2022 (2022-10-14), ANONYMOUS: "Mela Toning BB Cream SPF 50+ PA+++", XP093058640, retrieved from https://www.gnpd.com/sinatra/recordpage/9893832/ Database accession no. 9893832 * |
| DATABASE GNPD [online] MINTEL; 15 February 2021 (2021-02-15), ANONYMOUS: "Perfect Spot Erasing Puff Concealer SPF 30 PA++", XP093058651, retrieved from https://www.gnpd.com/sinatra/recordpage/8485741/ Database accession no. 8485741 * |
| DATABASE GNPD [online] MINTEL; 18 May 2022 (2022-05-18), ANONYMOUS: "Age Immune Serum", XP093058776, retrieved from https://www.gnpd.com/sinatra/recordpage/9610044/ Database accession no. 9610044 * |
| DATABASE GNPD [online] MINTEL; 30 June 2021 (2021-06-30), ANONYMOUS: "NCEF-Shot Supreme Polyrevitalising Concentrate", XP093058796, retrieved from https://www.gnpd.com/sinatra/recordpage/8836023/ Database accession no. 8836023 * |
| FITSIALOS GCHASSOT AATURCHI LDAYEM MALEBRIGAND KMOREILHON CMENEGUZZI GBUSCÀ RMARI BBARBRY P: "Transcriptional signature of epidermal kératinocytes subjected to in vitro scratch wounding reveals sélective roles for ERK1/2, p38, and phosphatidylinositol 3-kinase signaling pathways", J BIOL CHEM., vol. 282, no. 20, 18 May 2007 (2007-05-18), pages 15090 - 102 |
| MICHEL MTΔRΔK NGODBOUT MJLUSSIER MGAUDREAU PROYAL AGERMAIN L: "Keratin 19 as a bio-chemical marker of skin stem cells in vivo and in vitro: keratin 19 expressing cells arc differentially localized in function of anatomic sites, and their number varies with donor age and culture stage", J CELL SCI, vol. 109, May 1996 (1996-05-01), pages 1017 - 28 |
| PATRICIA ROUSSELLEFABIENNE BRAYEGUILA DAYAN: "Advanced Drug Delivery Reviews", vol. 146, 2019, ELSEVIER, article "Re-epithelialization of adult skin wounds: cellular mechanisms and therapeutic strategies", pages: 344 - 365 |
| RIDLEY AJ: "Rho GTPase signalling in cell migration", CURR OPIN CELL BIOL, vol. 36, October 2015 (2015-10-01), pages 103 - 12 |
| YOSHIDA AKANNO HWATABE DAKASAKA TSAWAI T: "The rôle of heparin-binding EGF-like growth factor and amphiregulin in the epidermal prolifération of psoriasis in coopération with TNFalpha", ARCH DERMATOL RES, vol. 300, no. 1, January 2008 (2008-01-01), pages 37 - 45, XP037911847, DOI: 10.1007/s00403-007-0809-y |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024133074A1 (en) | 2024-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5312795B2 (en) | Composition for improving skin condition and appearance and method of use thereof | |
| FR2916977A1 (en) | STIMULATION OF SYNTHESIS OF MCR1, MCR2 AND μ OPIOID RECEPTORS. | |
| FR2903903A1 (en) | USE OF A RICE PROTEIN HYDROLYZATE AS A PIGMENTANT ACTIVE INGREDIENT | |
| EP1837013B1 (en) | Composition comprising hydroxyapatite and a calcium salt for reinforcing the barrier function of the skin and/or semi-mucus membranes. | |
| EP1278532B1 (en) | Plant extract of the olea europaea species as no-synthase inhibitor and uses | |
| EP3980124A1 (en) | Extract of moringa peregrina seed cake, method for obtaining same and use thereof in cosmetic or nutricosmetic compositions | |
| EP1269988B1 (en) | Cosmetic or dermatological composition comprising acylaminoamide derivatives | |
| EP0993826A1 (en) | Use of a sanguisorba officinalis extract to stimulate the skin- and/or the hair-pigmentation | |
| EP3253457B1 (en) | Cosmetic use of a pepermint extract | |
| WO1998019664A2 (en) | Use of a potentilla erecta extract in the cosmetic and pharmaceutical field | |
| WO2016092179A1 (en) | Active complex for a skin anti-ageing cosmetic | |
| CA2322149A1 (en) | Use of a compound inhibiting the activity of a sodium channel and a calcium channel in a composition for topical use | |
| FR2997853A1 (en) | Reducing or delaying the thinning of skin and the sagging of skin and stimulating cellular metabolism of keratinocytes, comprises applying effective quantity of an extract of Myrothamnus flabellifolia to skin | |
| FR2844198A1 (en) | Restricting complement activating side-effects in skin, mucosa and/or scalp, e.g. for combating irritation due to other active agents, using activator of production of protectin or its precursor | |
| FR3143356A1 (en) | Combination of vitamins B1, B6 and B9 topically | |
| EP3980123B1 (en) | Moringa peregrina seed extract rich in 2,5-diformylfuran, process for obtaining same and use thereof in cosmetic compositions | |
| FR2769504A1 (en) | USE OF HONEY AS AN AGENT FOR REDUCING THE ADHESION OF MICROORGANISMS | |
| EP1174120B1 (en) | Use of an extract of an Iridaceae in an immune defenses stimulating composition | |
| FR2885802A1 (en) | Cosmetic use of a vitamin K in a composition as an agent to improve and/or repair the barrier function of skin or semi-mucous membranes | |
| FR3076461A1 (en) | Cosmetic composition of active prevention signs of age. | |
| EP1316301A1 (en) | Cosmetic or dermatological composition containing a retinoid and/or a carotenoid and acexamic acid | |
| FR2831443A1 (en) | The use of extracts of Gingko biloba or Olea europaea in cosmetic compositions intended to prevent, treat or palliate conditions of skin dryness linked to deficiencies in skin barrier function | |
| FR2859102A1 (en) | USE OF A RHODIOLA CRENULATA EXTRACT BY TOPIC | |
| FR2991168A1 (en) | Cosmetic and/or dermatological composition used e.g. to improve and/or reinforce barrier function of skin and protection of skin against external aggressions, includes extract of Laminaria ochroleuca and extract of Aphanizomenon flos-aquae | |
| OA21067A (en) | Moringa Peregrina seed extract rich in 2,5-diformylfuran, its process for obtaining it and its use in cosmetic compositions. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20240621 |